Study summary

Fedratinib shrank spleens in people who had stopped benefiting from ruxolitinib

FREEDOM2 trial · 201 people, phase 3 · Published September 2024, Lancet Haematology

36%had a 35%+ spleen shrinkage, vs 6% with best available therapy

What was tested

Fedratinib, a JAK2 inhibitor, against best available therapy, for myelofibrosis that had stopped responding to, or could not tolerate, ruxolitinib.

What they found

Spleen shrinkage of at least 35%: 36% vs 6%.
Severe treatment-related side effects occurred in 40% vs 12%, mostly anemia and low platelets.

What it means

Confirmed fedratinib as an option after ruxolitinib.

Lancet Haematol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.